Compile Data Set for Download or QSAR
Report error Found 118 Enz. Inhib. hit(s) with all data for entry = 8328
TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241779(US9409917, 77 | US9409917, 105 | US9409917, 104 | ...)
Affinity DataIC50: 1.30nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241720(US9409917, 18 | US9409917, 17)
Affinity DataIC50: 1.30nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241725(US9409917, 22)
Affinity DataIC50: 1.5nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241720(US9409917, 18 | US9409917, 17)
Affinity DataIC50: 1.60nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241706(US9409917, 98 | US9409917, 96 | US9409917, 97 | US...)
Affinity DataIC50: 1.80nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241743(US9409917, 40)
Affinity DataIC50: 2.70nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241727(US9409917, 25 | US9409917, 24)
Affinity DataIC50: 2.70nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241706(US9409917, 98 | US9409917, 96 | US9409917, 97 | US...)
Affinity DataIC50: 2.70nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241706(US9409917, 98 | US9409917, 96 | US9409917, 97 | US...)
Affinity DataIC50: 2.90nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241715(US9409917, 12)
Affinity DataIC50: 3.10nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241782(US9409917, 80 | US9409917, 79)
Affinity DataIC50: 4.10nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241779(US9409917, 77 | US9409917, 105 | US9409917, 104 | ...)
Affinity DataIC50: 4.70nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241714(US9409917, 11)
Affinity DataIC50: 4.80nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241804(US9409917, 110 | US9409917, 109 | US9409917, 102 |...)
Affinity DataIC50: 5.5nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241754(US9409917, 51)
Affinity DataIC50: 5.60nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241722(US9409917, 19)
Affinity DataIC50: 6.30nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241770(US9409917, 67)
Affinity DataIC50: 7.30nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241779(US9409917, 77 | US9409917, 105 | US9409917, 104 | ...)
Affinity DataIC50: 9.5nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241814(US9409917, 112 | US9409917, 111)
Affinity DataIC50: 9.5nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241737(US9409917, 34)
Affinity DataIC50: 10.7nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241804(US9409917, 110 | US9409917, 109 | US9409917, 102 |...)
Affinity DataIC50: 11nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241796(US9409917, 93)
Affinity DataIC50: 11.4nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241742(US9409917, 39)
Affinity DataIC50: 11.8nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241726(US9409917, 23)
Affinity DataIC50: 12.2nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241817(US9409917, 114)
Affinity DataIC50: 12.5nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241719(US9409917, 16)
Affinity DataIC50: 12.6nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241724(US9409917, 21)
Affinity DataIC50: 12.9nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241771(US9409917, 68)
Affinity DataIC50: 13.8nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241775(US9409917, 72)
Affinity DataIC50: 14.6nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241734(US9409917, 31)
Affinity DataIC50: 16nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241744(US9409917, 41)
Affinity DataIC50: 16.3nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241706(US9409917, 98 | US9409917, 96 | US9409917, 97 | US...)
Affinity DataIC50: 18.3nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241706(US9409917, 98 | US9409917, 96 | US9409917, 97 | US...)
Affinity DataIC50: 20nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241776(US9409917, 73)
Affinity DataIC50: 20.2nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241779(US9409917, 77 | US9409917, 105 | US9409917, 104 | ...)
Affinity DataIC50: 20.6nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241762(US9409917, 83 | US9409917, 84 | US9409917, 81 | US...)
Affinity DataIC50: 20.8nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241735(US9409917, 32)
Affinity DataIC50: 25nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241729(US9409917, 26)
Affinity DataIC50: 25.6nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241757(US9409917, 54)
Affinity DataIC50: 25.8nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241762(US9409917, 83 | US9409917, 84 | US9409917, 81 | US...)
Affinity DataIC50: 29nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241777(US9409917, 75 | US9409917, 74)
Affinity DataIC50: 35.3nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241818(US9409917, 115)
Affinity DataIC50: 35.4nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241816(US9409917, 113)
Affinity DataIC50: 35.9nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241773(US9409917, 71 | US9409917, 70)
Affinity DataIC50: 36.5nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241748(US9409917, 45)
Affinity DataIC50: 37.2nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241727(US9409917, 25 | US9409917, 24)
Affinity DataIC50: 39.4nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241758(US9409917, 55)
Affinity DataIC50: 41.6nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241745(US9409917, 42)
Affinity DataIC50: 46.9nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241765(US9409917, 62)
Affinity DataIC50: 46.9nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM241782(US9409917, 80 | US9409917, 79)
Affinity DataIC50: 51.1nMT: 2°CAssay Description:HEK cells stably expressing P2X7 were used to screen drugs using the YO-PRO1 assay. Cells were grown to confluency in adherent culture at 37° C. ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
US Patent

Displayed 1 to 50 (of 118 total ) | Next | Last >>
Jump to: